Advertisement

Advertisement
Immunotherapy

How Turning ‘Cold’ Tumors Into ‘Hot’ Ones May Improve Response to Immunotherapy

The proliferation of immunotherapeutics in the treatment of cancer over the past decade has revolutionized the way many cancers are treated, especially lung cancer and melanoma...

Myelodysplastic Syndromes

Novel Treatments of Myelodysplastic Syndromes

As part of The ASCO Post’s continued coverage of the 2018 American Society of Hematology Annual Meeting & Exposition, here is an update on seven different studies on new therapeutics...

Lung Cancer

Encourage Lung Cancer Screening to Prevent Early Deaths

Discussions of benefits and harms from screening of high-risk populations for lung cancer have missed the point. The National Lung Screening Trial (NLST) showed an early and statistically significant...


Advertisement
Lung Cancer

Lorlatinib Shows Overall and Intracranial Activity in ALK-Positive NSCLC

In a global phase II study reported in The Lancet OncologyBenjamin J. Solomon, MBBS, of Peter MacCallum Cancer Centre, Melbourne, and colleagues found that lorlatinib...

Lymphoma
Survivorship

Living My Best Life

But then my life took a drastic turn. Suddenly, a lump popped up on the left side of my neck, which I initially attributed to my body’s way of fighting off an infection...

 

Advertisement




More Top Stories

Issues in Oncology
Symptom Management

Alok A. Khorana, MD, on Reducing VTE Associated With Systemic Cancer Therapy: Results From the CASSINI Trial

Integrative Oncology

Integrative Oncology Scholars Program: Model for Evidence-Based Complementary Care

THE FIRST full year of educational training in the practice of complementary therapies is now underway at the University of Michigan in Ann Arbor through its Integrative Oncology Scholars Program, which launched in 2017. The program, which is supported through a 5-year grant from the National...

Advertisement

New Approach to Predicting Response to Pertuzumab and Trastuzumab in Breast Cancer

In the phase II TBCRC026 study reported in the Journal of Clinical Oncology, Connolly et al found that early changes in tumor maximum standardized uptake values corrected for lean body mass (SULmax) on [18F]fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) were...

Breast Cancer

Monica Morrow, MD, on View From the Trenches: What Will You do on Monday Morning?

Leukemia
Lymphoma

FDA Approves Ibrutinib in Combination With Obinutuzumab in Treatment-Naive CLL/SLL

ON JANUARY 28, 2019, the U.S. Food and Drug Administration (FDA) approved ibrutinib (Imbruvica), a Bruton’s tyrosine kinase inhibitor, in combination with obinutuzumab in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). This is the first approval of ...

New ASCO Answers Fact Sheet: When the Doctor Says ‘Cancer’

People diagnosed with cancer often say they were stunned when they heard the news of their diagnosis, and were unable to process what their health-care provider said afterward. Give your patients easy-to-understand information they can take home with them. When the Doctor Says “Cancer” is a 1-page...

Involvement of Primary Care Providers in Cancer Treatment Decisions

The idea of team-based cancer care most often focuses on involving primary care physicians in the care of cancer survivors, but research has shown patients are also discussing initial cancer treatment options with their primary care doctors. Now, a new study by Wallner et al in Cancer has...

Skin Cancer
Lymphoma

Steven M. Horwitz, MD, on PTCL and CTCL: Trial Results on Cerdulatinib

Issues in Oncology

Clinical Cancer Advances 2019: ASCO Names Advance of the Year, Debuts Research Priorities for the Cancer Community

In the release of its annual report on progress against cancer, Clinical Cancer Advances 2019, ASCO recognized progress in treating rare cancers as the Advance of the Year. The report catalogs a year’s worth of remarkable research advancements, reinforces the need for continued federal research...

Advertisement

System-Based Intervention to Reduce Racial Disparities in Early-Stage Lung Cancer Treatment

Results from a study published by Cykert et al in Cancer Medicine showed that a pragmatic system-based intervention within cancer treatment centers may eliminate existing disparities in treatment and outcomes for black patients with early-stage lung cancer. “These results show ...